SLC6A3 and Parkinson disease: Based on the results of DAT-PET, we suspect two of the participants with Parkinson’s disease (one included in the longitudinal study) to be scans without evidence of dopamine deficit subjects due to their relatively high putamen DAT availability and unresponsiveness to carbidopa/levodopa.